Valganciclovir (valganciclovir) medical insurance reimbursement status and patient out-of-pocket cost reference

Valganciclovir (Valganciclovir) is a broad-spectrum antiviral drug mainly used to prevent and treat cytomegalovirus (CMV) infection in organ transplant patients and other CMV-related diseases in immunosuppressed states. At present, the drug is already on the market in China, but it has not yet been included in the scope of medical insurance reimbursement, so patients need to bear all the drug costs themselves. The latest domestic price of 0.45g*60 tablets is about 14,000 to 5,000 yuan, which is a large financial burden for some patients.

In overseas markets, Vancevi has a variety of versions to choose from, including original drugs imported from Switzerland, Indian versions and Turkish versions, with prices ranging from 4,000 to 5,000 yuan to more than 15,000 yuan. Since pricing, exchange rates and import tariffs differ in different countries and regions, patients should understand the specific costs and transportation compliance in advance when purchasing drugs overseas to ensure that the source of the drugs is formal and avoid purchasing from uncertified channels.

In addition, the generic version of Vancevit launched by Lucius Pharmaceuticals in Laos has been officially launched overseas. Its drug ingredients are basically the same as the original drug, but the price is more affordable, about more than 1,000 yuan. For patients with limited financial resources or who wish to reduce the cost of treatment, generic drugs provide a viable alternative. However, whether you choose original drugs or generic drugs, you should ensure that they are obtained through formal channels and used under the guidance of professional doctors to ensure drug safety and efficacy.
Generally speaking, since Vancevi has not yet been included in medical insurance in China, patients have a high proportion of out-of-pocket payments, so financial arrangements need to be made in advance. During the process of purchasing and using drugs, it is recommended to rationally choose drug versions and drug purchasing channels based on the patient's own condition, economic conditions and doctor's advice. At the same time, patients should closely monitor hematological indicators and liver and kidney functions during long-term use, and adjust the medication regimen in a timely manner to ensure the safety and effectiveness of treatment.
Reference: https://www.drugs.com/